Perrigo (PRGO) Liabilities and Shareholders Equity (2013 - 2026)
Perrigo's (PRGO) quarterly Liabilities and Shareholders Equity came in at $8.0 billion in Q1 2026, down 18.2% year-on-year from $9.8 billion in Q1 2025, and down 6.47% on a QoQ basis from $8.5 billion in Q4 2025.
Perrigo (PRGO) Liabilities and Shareholders Equity (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $8.0 billion in Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity fell 18.2% year-over-year to $8.0 billion in Q1 2026; TTM through Mar 2026 was $36.7 billion, a 10.51% decrease from a year earlier, with the FY2025 full-year figure at $8.5 billion, down 11.53% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $8.0 billion, down from $8.5 billion in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for PRGO reached as high as $11.2 billion in Q3 2024 and fell as low as $8.0 billion in Q1 2026.
- Historically, Liabilities and Shareholders Equity has averaged $10.3 billion across 5 years, with a median of $10.6 billion in 2024.
- Across the five-year window, Liabilities and Shareholders Equity gained 5.67% in 2022 and slipped 18.2% in 2026, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $11.0 billion in 2022, then decreased by 1.89% to $10.8 billion in 2023, then dropped by 10.74% to $9.6 billion in 2024, then fell by 11.53% to $8.5 billion in 2025, then decreased by 6.47% to $8.0 billion in 2026.
- Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $8.0 billion in Q1 2026, $8.5 billion in Q4 2025, and $10.1 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.40 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.04 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.15 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 98.91 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.71 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 69.30 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 36.83 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.91 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.22 Bn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn | 7.98 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 7.98 Bn |
| Dec 31, 2025 | 8.54 Bn |
| Sep 27, 2025 | 10.08 Bn |
| Jun 28, 2025 | 10.09 Bn |
| Mar 29, 2025 | 9.76 Bn |
| Dec 31, 2024 | 9.65 Bn |
| Sep 28, 2024 | 11.20 Bn |
| Jun 29, 2024 | 10.40 Bn |
| Mar 30, 2024 | 10.64 Bn |
| Dec 31, 2023 | 10.81 Bn |
| Sep 30, 2023 | 10.76 Bn |
| Jul 1, 2023 | 10.96 Bn |
| Apr 1, 2023 | 10.95 Bn |
| Dec 31, 2022 | 11.02 Bn |
| Oct 1, 2022 | 10.68 Bn |
| Jul 2, 2022 | 10.92 Bn |
| Apr 2, 2022 | 10.39 Bn |
| Dec 31, 2021 | 10.43 Bn |
| Oct 2, 2021 | 10.92 Bn |
| Jul 3, 2021 | 11.23 Bn |